Hypothesis Bio
Hypothesis develops precision enzyme-based skincare products that selectively target harmful bacteria—Staph aureus and C. acnes—driving eczema flare-ups and acne breakouts while preserving beneficial skin microbiota. The company's proprietary TPZ-01™ and CUT-02™ enzymes are clinically tested, with trials showing a 97% reduction in breakouts for acne patients and a 2.5x greater effectiveness versus standard eczema treatments.
- Biotechnology
- Commerce & Shopping
- Consumer Goods
- Healthcare Technology
- Software Only
- Wellness & Fitness Technology
Funding
Founders
Product
Problem
Conventional treatments for eczema and acne either address only surface-level symptoms while ignoring the underlying bacterial imbalances, or they wipe out all bacteria—both harmful and beneficial—damaging the skin's microbiome. This leaves patients with recurring flare-ups, compromised skin barriers, and a vulnerable microbial ecosystem that fails to return to a healthy state.
Solution
Hypothesis offers a line of precision enzyme-based skincare products that selectively target the specific harmful bacteria responsible for skin conditions while leaving beneficial microbes intact. The TPZ-01™ enzyme targets Staph aureus, which drives up to 90% of eczema flares, while the CUT-02™ enzyme targets C. acnes, the bacteria behind acne breakouts. This precision approach allows the skin microbiome to rebalance naturally, promoting lasting relief rather than temporary symptom suppression. Products span eczema therapy creams, hydrogels, healing sprays, acne cleansers, serums, and blemish patches, all formulated with purposeful, microbiome-friendly ingredients.
Target Audience
Primary customers are individuals with eczema-prone or acne-prone skin—including parents seeking safe, steroid-free solutions for children—who have not found adequate relief from conventional treatments and are seeking science-backed, microbiome-friendly alternatives.
Features
- Proprietary TPZ-01™ enzyme targets Staph aureus to address eczema flares while preserving beneficial skin bacteria
- Proprietary CUT-02™ enzyme selectively targets C. acnes for acne treatment without microbiome disruption
- Clinical trial results show 97% of acne participants saw fewer breakouts and 81% saw reduction in inflamed pimples
- Eczema trials demonstrate 2.5x greater effectiveness than a standard colloidal oatmeal-based treatment and significant reduction in Staph aureus on skin
- Products formulated with complementary barrier-repairing ingredients including ceramides, colloidal oatmeal, and hyaluronic acid
- EWG Verified®, NEA Accepted, dermatologist-approved, hypoallergenic, fragrance-free, and certified microbiome-friendly formulas
- Research funding from the National Institutes of Health (NIH) with peer-reviewed validation